A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)

Journal of Thoracic and Cardiovascular Surgery

Volumn 143, Issue 5, 2012, Pages 1022-1029

  Bokesch, Paula M ^a,b   Szabo, Gabor ^c   Wojdyga, Ryszard ^d   Grocott, Hilary P ^e   Smith, Peter K ^f   Mazer, C David ^g   Vetticaden, Santosh ^a   Wheeler, Alistair ^a   Levy, Jerrold H ^h  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e UNIVERSITY OF MANITOBA   (Canada)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALLANTIDE; HEPARIN; TRANEXAMIC ACID;

AGED; AORTA VALVE REPLACEMENT; AORTIC VALVE REPAIR; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOSPITAL DISCHARGE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPAIR; MITRAL VALVE REPLACEMENT; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PATIENT MONITORING; PERIOPERATIVE BLOOD LOSS; PERIOPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SEIZURE; SIDE EFFECT; THROMBOCYTE TRANSFUSION; TRICUSPID VALVE REPAIR; TRICUSPID VALVE REPLACEMENT;

AGED; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; ERYTHROCYTE TRANSFUSION; EUROPE; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME; UNITED STATES;

EID: 84856971781     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.06.001     Document Type: Article

References (27)

1. Herwaldt LA, Swartzendruber SK, Edmond MB, Embrey RP, Wilkerson KR, Wenzel RP, et al. The epidemiology of hemorrhage related to cardiothoracic operations. Infect Control Hosp Epidemiol. 1998;19:9-16. (Pubitemid 128472656)
2. Herwaldt LA, Swartzendruber SK, Zimmerman MB, Scholz DA, Franklin JA, Caldarone CA. Hemorrhage after coronary artery bypass graft procedures. Infect Control Hosp Epidemiol. 2003;24:44-50. (Pubitemid 36083922)
3. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, et al. Re-exploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg. 1998;133:442-7. (Pubitemid 28193531)
4. Koch CG, Li L, VanWagoner DR, Duncan AI, Gillinov AM, Blackstone EH. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg. 2006;82:1747-56. (Pubitemid 44596264)
5. Ternstrom L, Radulovic V, Karlsson M, Baghaei F, Hyllner M, Bylock A, et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res. 2010; 126:e128-33.
6. Pouplard C, Regina S, May MA, Gruel Y. Heparin-induced thrombocytopenia: a frequent complication after cardiac surgery. Arch Mal Coeur Vaiss. 2007;100:563-8. (Pubitemid 47234428)
7. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980;56:824-34. (Pubitemid 11242975)
8. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007;44:82-94. (Pubitemid 44647107)
9. McEvoy MD, Reeves ST, Reves JG, Spinale FG. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg. 2007;105:949-62.
10. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg. 1997;85:963-70. (Pubitemid 27471507)
11. Brown JR, Toler AW, Kramer RS, Landis RC. Anti-inflammatory effect of aprotinin: a meta-analysis. J Extra Corpor Technol. 2009;41:79-86.
12. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;CD001886.
13. Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008;8:1187-99.
14. Ohri SK, Parratt R, White T, Becket J, Brannan JJ, Hunt BJ, et al. A genetically engineered human Kunitz protease inhibitor with increased kallikrein inhibition in an ovine model of cardiopulmonary bypass. Perfusion. 2001;16:199-206. (Pubitemid 32519804)
15. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999;57:233-60. (Pubitemid 29116517)
16. Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol. 2010;6:29-39.
17. Segal H, Hunt BJ. Aprotinin: pharmacological reduction of perioperative bleeding. Lancet. 2000;355:1289-90. (Pubitemid 30198995)
18. Homi HM, Arepally GM, Sheng H, Grocott HP. The effect of kallikrein inhibition in a rat model of stroke during cardiopulmonary bypass [abstract]. Anesthesiology. 2010;107:A2136.
19. Data on File. DX-88/3, 2008 Dyax Corp; DX-88/16, 2009, Cubist Clinical Study Reports.
20. Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5 Suppl):S27-86. (Pubitemid 46621124)
21. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis. 1994;5:537-42. (Pubitemid 24301574)
22. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass - effects on the Hageman factor (FXII) - kallikrein system and blood loss. Blood Coagul Fibrinolysis. 1992;3:99-104.
23. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost. 1997;78:1021-6. (Pubitemid 27417294)
24. Bayer Healthcare Pharmaceuticals. Trasylol® (aprotinin injection) [Prescribing Information]. West Haven CT: Bayer Healthcare Pharmaceuticals; 2006.
25. Dyax Corp. Kalbitor (ecallantide) Injection Prescribing Information. Cambridge, MA: Dyax Corp; 2009.
26. Edmunds LH Jr, Colman RW. Bleeding that won't stop. Ann Thorac Surg. 2008; 85:1153-4. (Pubitemid 351381709)
27. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-31. (Pubitemid 351749156)